Novo Enterprise Value Over E B I T D A from 2010 to 2024
NVO Stock | USD 135.28 2.48 1.87% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 27.83656628 | Current Value 29.23 | Quarterly Volatility 8.58122054 |
Check Novo Nordisk financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novo main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.9 B, Interest Expense of 429.4 M or Selling General Administrative of 6.5 B, as well as many exotic indicators such as Price To Sales Ratio of 14.16, Dividend Yield of 0.0178 or PTB Ratio of 30.85. Novo financial statements analysis is a perfect complement when working with Novo Nordisk Valuation or Volatility modules.
Novo | Enterprise Value Over E B I T D A |
Latest Novo Nordisk's Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Novo Nordisk AS over the last few years. It is Novo Nordisk's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novo Nordisk's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
Timeline |
Novo Enterprise Value Over E B I T D A Regression Statistics
Arithmetic Mean | 14.92 | |
Geometric Mean | 12.12 | |
Coefficient Of Variation | 57.51 | |
Mean Deviation | 6.85 | |
Median | 13.93 | |
Standard Deviation | 8.58 | |
Sample Variance | 73.64 | |
Range | 27.7614 | |
R-Value | 0.96 | |
Mean Square Error | 5.85 | |
R-Squared | 0.93 | |
Slope | 1.85 | |
Total Sum of Squares | 1,031 |
Novo Enterprise Value Over E B I T D A History
About Novo Nordisk Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Novo Nordisk income statement, its balance sheet, and the statement of cash flows. Novo Nordisk investors use historical funamental indicators, such as Novo Nordisk's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Novo Nordisk investors may use each financial statement separately, they are all related. The changes in Novo Nordisk's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novo Nordisk's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novo Nordisk Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novo Nordisk. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Enterprise Value Over EBITDA | 27.84 | 29.23 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Novo Nordisk Correlation against competitors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Transaction History View history of all your transactions and understand their impact on performance | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.294 | Earnings Share 2.84 | Revenue Per Share 54.605 | Quarterly Revenue Growth 0.225 | Return On Assets 0.2524 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.